Shares of Danish company NovoNordisk (NOVOB.DK) are gaining nearly 11% and climbing to historic highs. The reason is the results of a study of the obesity-fighting drug Wegovy. They indicated that the drug can reduce the risk of heart disease in overweight adults by up to 20%. The market sees chances that the company is in possession of a drug that effectively helps combat chronic obesity and reduces the risk of its complications.
- In a double-blind trial, Wegovy (semaglutide) was administered to a group of 17,604 adults with obesity and cardiovascular disease (no history of diabetes, data from more than 800 centers and 41 countries) over the age of 45 for up to five years;
- To date, there are no approved weight-reduction drugs that provide effective weight control while reducing the risk of heart attack, stroke or death from cardiovascular causes;
- Novo Nordisk will apply for regulatory approval (FDA) and expanded indications for Wegovy 2.4 mg in the US and EU later this year. It will also present the scientific behind-the-scenes of the study and its results at a scientific conference, also scheduled for 2023.
NovoNordisk shares, D1 interval. Shares are climbing at ATH levels above 1200 DK per share. Source: xStation5
